These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 12109650)

  • 1. Gammalinolenic acid treatment of fatigue associated with primary Sjögren's syndrome.
    Theander E; Horrobin DF; Jacobsson LT; Manthorpe R
    Scand J Rheumatol; 2002; 31(2):72-9. PubMed ID: 12109650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients with primary Sjögren's syndrome treated for two months with evening primrose oil.
    Oxholm P; Manthorpe R; Prause JU; Horrobin D
    Scand J Rheumatol; 1986; 15(2):103-8. PubMed ID: 3529370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome.
    Bowman SJ; Everett CC; O'Dwyer JL; Emery P; Pitzalis C; Ng WF; Pease CT; Price EJ; Sutcliffe N; Gendi NST; Hall FC; Ruddock SP; Fernandez C; Reynolds C; Hulme CT; Davies KA; Edwards CJ; Lanyon PC; Moots RJ; Roussou E; Giles IP; Sharples LD; Bombardieri M
    Arthritis Rheumatol; 2017 Jul; 69(7):1440-1450. PubMed ID: 28296257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of total glucosides of peony in the treatment of primary Sjögren's syndrome: a multi-center, randomized, double-blinded, placebo-controlled clinical trial.
    Liu X; Li X; Li X; Li Z; Zhao D; Liu S; Zhang M; Zhang F; Zhu P; Chen J; Wei W; Lin B; Zhou Y; Chen J; Pang Y; Zhang L; Sun X; Yu Z; Jia Y; Wang J; Sun W; Chiu F; Pang L; Wang G
    Clin Rheumatol; 2019 Mar; 38(3):657-664. PubMed ID: 30280368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study.
    Mariette X; Seror R; Quartuccio L; Baron G; Salvin S; Fabris M; Desmoulins F; Nocturne G; Ravaud P; De Vita S
    Ann Rheum Dis; 2015 Mar; 74(3):526-31. PubMed ID: 24347569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Essential fatty acid and prostaglandin metabolism in Sjögren's syndrome, systemic sclerosis and rheumatoid arthritis.
    Horrobin DF
    Scand J Rheumatol Suppl; 1986; 61():242-5. PubMed ID: 3296151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial.
    Gottenberg JE; Ravaud P; Puéchal X; Le Guern V; Sibilia J; Goeb V; Larroche C; Dubost JJ; Rist S; Saraux A; Devauchelle-Pensec V; Morel J; Hayem G; Hatron P; Perdriger A; Sene D; Zarnitsky C; Batouche D; Furlan V; Benessiano J; Perrodeau E; Seror R; Mariette X
    JAMA; 2014 Jul; 312(3):249-58. PubMed ID: 25027140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary Sjögren's syndrome treated with Efamol/Efavit. A double-blind cross-over investigation.
    Manthorpe R; Hagen Petersen S; Prause JU
    Rheumatol Int; 1984; 4(4):165-7. PubMed ID: 6385206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic omega-6 essential fatty acid treatment and pge1 tear content in Sjögren's syndrome patients.
    Aragona P; Bucolo C; Spinella R; Giuffrida S; Ferreri G
    Invest Ophthalmol Vis Sci; 2005 Dec; 46(12):4474-9. PubMed ID: 16303936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity.
    Dörner T; Posch MG; Li Y; Petricoul O; Cabanski M; Milojevic JM; Kamphausen E; Valentin MA; Simonett C; Mooney L; Hüser A; Gram H; Wagner FD; Oliver SJ
    Ann Rheum Dis; 2019 May; 78(5):641-647. PubMed ID: 30826774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Sjögren's syndrome: an overview.
    Manthorpe R; Prause JU
    Scand J Rheumatol Suppl; 1986; 61():237-41. PubMed ID: 3296150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-1 inhibition and fatigue in primary Sjögren's syndrome--a double blind, randomised clinical trial.
    Norheim KB; Harboe E; Gøransson LG; Omdal R
    PLoS One; 2012; 7(1):e30123. PubMed ID: 22253903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study.
    Dass S; Bowman SJ; Vital EM; Ikeda K; Pease CT; Hamburger J; Richards A; Rauz S; Emery P
    Ann Rheum Dis; 2008 Nov; 67(11):1541-4. PubMed ID: 18276741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Traditional Chinese medicine compound ShengJinRunZaoYangXue granules for treatment of primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled clinical trial.
    Hu W; Qian X; Guo F; Zhang M; Lyu C; Tao J; Gao Z; Zhou Z
    Chin Med J (Engl); 2014; 127(15):2721-6. PubMed ID: 25146603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary Sjögren's syndrome treated with Efamol/efavit. A double-blind cross-over investigation.
    Webb J; McCredie M
    Rheumatol Int; 1985; 5(4):191. PubMed ID: 4048763
    [No Abstract]   [Full Text] [Related]  

  • 16. Dehydroepiandrosterone (DHEA) substitution treatment for severe fatigue in DHEA-deficient patients with primary Sjögren's syndrome.
    Virkki LM; Porola P; Forsblad-d'Elia H; Valtysdottir S; Solovieva SA; Konttinen YT
    Arthritis Care Res (Hoboken); 2010 Jan; 62(1):118-24. PubMed ID: 20191499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS).
    Mariette X; Ravaud P; Steinfeld S; Baron G; Goetz J; Hachulla E; Combe B; Puéchal X; Pennec Y; Sauvezie B; Perdriger A; Hayem G; Janin A; Sibilia J
    Arthritis Rheum; 2004 Apr; 50(4):1270-6. PubMed ID: 15077311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary Sjögren's syndrome in Moroccan patients: characteristics, fatigue and quality of life.
    Ibn Yacoub Y; Rostom S; Laatiris A; Hajjaj-Hassouni N
    Rheumatol Int; 2012 Sep; 32(9):2637-43. PubMed ID: 21786120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current and potential treatments for primary Sjögren's syndrome.
    Mariette X
    Joint Bone Spine; 2002 Jun; 69(4):363-6. PubMed ID: 12184431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of omega-3 and vitamin E supplementation on dry mouth in patients with Sjögren's syndrome.
    Singh M; Stark PC; Palmer CA; Gilbard JP; Papas AS
    Spec Care Dentist; 2010; 30(6):225-9. PubMed ID: 21044101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.